Arcus Biosciences
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Arcus Biosciences sits in the top decile of US sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count).
Arcus Biosciences: 25 sponsored US clinical trials, 3 recruiting.
Arcus Biosciences sponsors 25 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 14 completed. 3 of these trials are in Phase 3-4 (later-stage) and 22 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Cancer, with 2 trials.
Top-decile sponsor footprint
Arcus Biosciences ranks in the top decile of sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
14 of 14 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
25 total, page 1 of 1
A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult Participants
NCT07641881
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
NCT05536141
Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)
NCT07364214
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT06608927
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
NCT06120075
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
NCT05891171
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
NCT05568095
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
NCT05329766
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
NCT04736173
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
NCT04104672
Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)
NCT06919991
A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers
NCT05999513
A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants
NCT05277012
A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants
NCT05154136
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
NCT04660812
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
NCT04772989
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
NCT04381832
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
NCT04262856
Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors
NCT04087018
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer
NCT03846310
A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies
NCT03720678
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
NCT03719326
A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
NCT03628677
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
NCT03629756
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 19 |
| Phase 2 | 3 |
| Phase 3 | 3 |
Therapeutic Areas
What is open in the Arcus Biosciences pipeline
3 recruiting of 25 indexed (12% open); 14 completed (56%).
Phase mix: 3 late (III/IV) vs 22 early (I/II) (early-phase heavy).
Top condition: Advanced Cancer (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Arcus Biosciences: open-pipeline peers nationwide
Peers matched on 25 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
Arcus Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 25 trials (± recruiting share)
- Arcutis Biotherapeutics · 25 trials · 8% recruiting
- Ardelyx · 25 trials · 12% recruiting
- Drexel University College of Medicine · 25 trials · 0% recruiting
- Fisher and Paykel Healthcare · 25 trials · 4% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Kyowa Kirin Co. · 12% recruiting · 25 trials
- Takeda · 12% recruiting · 408 trials
- East Carolina University · 12% recruiting · 58 trials
- National Institute of Dental and Craniofacial Research (NIDCR) · 12% recruiting · 91 trials
Related
What to do with this Arcus Biosciences page
25 registered trials is a research-attention snapshot, not an endorsement of Arcus Biosciences or any single study.
- 3 of Arcus Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Cancer is the condition Arcus Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Arcus Biosciences pipeline card: 25 registered trials from official public datasets.Report a data error.